Login to Your Account



Seeking spark in Pfizer asset, Gemphire files for IPO alongside preclinical Phaserx

By Michael Fitzhugh
Staff Writer

Tuesday, April 19, 2016

Gemphire Therapeutics Inc. and Phaserx Inc. have become the latest brave entrants to the biopharma IPO queue, joining 17 other contenders filed and pending, in a public financing climate significantly cooler than in 2015.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription